INTRODUCTION
The g-aminobutyric acid type A (GABA A ) receptor is one of the three main classes of receptors activated by GABA, the principal inhibitory neurotransmitter in the central nervous system. This receptor is an ionotropic, ligand-gated chloride ion channel that is usually situated in the post synaptic membrane of neurons. When activated, the ion channel becomes permeable to chloride anions, and under normal cell conditions in most mature neurons; the increased chloride conductance hyperpolarizes the resting potential of the membrane, preventing the generation of action potentials. Thus, the main effect of GABA A receptor activation is synaptic inhibition [Jacob et al., 2008] .
Not surprisingly, GABA A receptors play an important role in the brain, and genetic defects affecting their composition, assembly, and trafficking are implicated in a number of neurological and developmental disorders. Mutations in genes encoding some of the GABA A receptors subunits (GABRA1, GABRA6, GABRB3, GABRG2, and GABRD) underlie various forms of epilepsy Macdonald et al., 2010] . Copy number variations of 15q11-q13, a region containing the GABA A receptors subunit genes GABRA5, GABRB3, and GABRG3, are associated with some instances of autism [Hogart et al., 2010] , while duplications spanning 4p13-p12, containing the GABA A receptors subunit genes GABRA2, GABRA4, GABRB1, and GABRG1, are associated with a spectrum of neurodevelopmental disorders, including autism, developmental delay, and learning disabilities [Polan et al., 2014] .
To date, no human genetics studies have implicated mutations in GABRB2, encoding the b2 subunit of the GABA A receptor, with childhood epilepsy, intellectual disability, or other neurodevelopmental disorders. Here we present a 12-year-old girl with intellectual disability and epilepsy, who was discovered to have a potentially pathogenic novel missense variant in GABRB2. We present details of her clinical history and molecular testing, and we review some of the clinical consequences of GABA A receptor dysfunction.
CLINICAL REPORT
The proband is a 12-year-old girl from Spain who was referred to the Neurogenetics Clinic at the Kennedy Krieger Institute for an etiological evaluation of her intellectual disability and epilepsy.
She had an unremarkable birth history. The family history was negative for other individuals with epilepsy or neurodevelopmental disorders. Both parents as well as two older siblings were healthy.
She was doing well as a young infant until the age of 9 months, when she developed febrile seizures associated with the onset of chickenpox. She continued to have clusters of febrile seizures but eventually developed primarily non-febrile seizures. These were initially generalized tonic clonic convulsions that over the years evolved into more subtle spells associated with headache, dizziness, paleness, loss of consciousness, and certain emotions. She currently takes lamotrigine and clobazam for seizure control. Of note, the addition of clobazam had made significant improvement in the frequency of seizures.
Gradually, her development slowed over the years; she currently carries the diagnosis of intellectual disability. Although she attends regular school, she receives special tutoring half the day; she attends the other half mainly for socialization.
On her initial evaluation, when she was 12 years old, her growth parameters were unremarkable. She was non-dysmorphic, and the rest of her general exam was normal. On neurological exam, she appeared somewhat anxious, but she warmed up as the encounter proceeded. She spoke short, two to three word sentences in Spanish without any dysarthria but with significant perseveration. She followed two step commands. Overall, cognitively she appeared at the level of a 3 to 4-year-old. Her cranial nerves appeared normal. She had normal muscle tone and strength but was clumsy with fine motor movements. Sensation was grossly intact. Finger nose finger testing was normal; there was no ataxia. She was able to walk on her tiptoes but had difficulty walking on her heels or along a line, and seemed to be unable to replicate the examiner's movements. Stress gait assessment was deferred but there was bilateral flexure posturing of elbows when asked to run. Tendon reflexes were brisk at 3þ throughout, there was no clonus, and Babinski sign was negative.
She had a complete genetic workup that was unrevealing. Prior testing included karyotype, single-nucleotide polymorphism chromosome microarray, fragile X trinucleotide repeat analysis, plasma amino acids, urine organic acids, very long chain fatty acids, carbohydrate deficient transferrin analysis for congenital disorders of glycosylation, methylation analysis for Angelman syndrome, and a 38-gene "Infantile Epilepsy" NextGen sequencing panel performed at GeneDx Laboratory. Her brain MRI was normal. She had several EEGs in the past, showing bursts of spike and polyspikes against an otherwise normal background (see Fig. 1 ). Given the unrevealing nature of her prior workup, she underwent whole exome sequencing. 
METHODS
Whole exome sequencing was performed by GeneDx Laboratory on genomic DNA obtained from the proband, mother, and father. Exonic regions were targeted with the Agilent SureSelect XT2 All Exon V4 kit. Targeted regions were sequenced with the Illumina HiSeq 2000 sequencing system. Sequenced DNA was compared with the reference human genome assembly, GRCh37 hg19. A sequence variant was discovered in GABRB2. It was confirmed by dideoxy sequencing.
Several approaches were used to analyze the pathogenicity of the GABRB2 variant. The novelty of the variant was based on its absence from the Human Gene Mutation Database (http://www.hgmd.org/ ), National Heart, Lung, and Blood Institute (NHLBI) Exome Variant Server (http://evs.gs.washington.edu/EVS/), and Pubmed (http://www.ncbi.nlm.nih.gov/pubmed/). The primary protein structure of the variant was analyzed to see if the variant resulted in a non-conservative substitution, and if the variant occurred at a residue that was evolutionarily conserved, using sequence homologs from HomoloGene (http://www.ncbi.nlm.nih.gov/homologene/) and multiple sequence alignment with MAFFT (http:// mafft.cbrc.jp/alignment/software/). Disruption of protein function by the variant was determined with pathogenicity prediction software, PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/ index.shtml), which uses a Naïve Bayes classifier trained using supervised machine-learning and classifies variants as benign, possibly damaging, or probably damaging. Finally, the structural and functional importance of the variant was predicted by analyzing a related protein structure based on protein structural alignment using Protein Basic Local Alignment Search Tool (BLAST) (http:// blast.ncbi.nlm.nih.gov) against the Protein Data Bank (http:// www.rcsb.org/pdb/home/home.do).
RESULTS
Whole exome sequencing revealed a de novo heterozygous mutation in exon 4 of GABRB2 (c.236T > C; p.M79T). This variant is not found in the Human Gene Mutation Database or NHLBI Exome Variant Server, nor has it been reported in the literature. The variant resulted in the non-conservative substitution of methionine, a non-polar amino acid, with threonine, a polar amino acid. This position is evolutionarily conserved across multiple species (see Fig. 2a ). The variant was predicted to be possibly damaging based on analysis with PolyPhen-2.
Sequence alignment with Protein BLAST revealed statistically significant relatedness of human GABRB2 to each subunit of GluCla, a homopentameric glutamate-gated chloride channel found in Caenorhabditis elegans [Hibbs and Gouaux, 2011] (59% of query covered by alignment to the database sequence). See Figure 3a . M79 in human GABRB2 is conserved with a residue (M47) in the b2 structure of each subunit of GluCla. In GluCla, the b1-b2 loop is an extracellular domain loop that facilitates communication between the neurotransmitter site and the transmembrane pore. M47 in each subunit of GluCla is six residues away from the start of loop D, a stretch of seven amino acids within the b2 structure that forms part of the neurotransmitter site [Hibbs and Gouaux, 2011] . See Figure 3b .
DISCUSSION
The novel missense variant c.236T > C (p.M79T) in GABRB2 is likely pathogenic. The variant affects a position in the gene that is highly conserved across multiple species. Moreover, it results in the non-conservative substitution of a hydrophobic amino acid with a polar amino acid. Finally, in silico analysis with PolyPhen-2 predicts that the protein change resulting from this variant is possibly damaging.
The variant affects the b2 subunit of the structurally complex GABA A receptor. GABA A receptors are hetero-pentamers arranged from combinations of several different subunits, each with four transmembrane (TM) domains. There are 19 different subunits across eight subunit classes: a1-a6, b1-b3, g1-g3, d, e, u, p, and r1-r3 [Olsen and Sieghart, 2008] . The genes encoding these subunits are distributed across the genome, with the majority clustered on four chromosomes: chromosome 4p12 (GABRA2, GABRA4, GABRB1, GABRG1), 5q34 (GABRA1, GABRA6, GABRB2, GABRG2), 15q12 (GABRA5, GABRB3, GABRG3), and Xq28 (GABRA3, GABRE, GABRQ) [Russek, 1999] . See Table I . The extensive variety of subunits may suggest an equally diverse repertoire of possible receptor subtypes; however, this heterogeneity is limited by the requirements of a fully functional GABA A receptor to have, at minimum, an a subunit, b subunit, and one other subunit type [Olsen and Sieghart, 2008] .
In mammals, the most common configuration of the GABA A receptor is a complex comprising two a subunits, two b subunits, and one g subunit (though the d, e, u, or p subunit can take the place of the g subunit) (see Fig. 4 ). When the receptor is assembled, the five subunits come together so that the second TM domain lines the central pore of the ion channel. The N-terminal region is the binding site for GABA, in the a/b interface. The intracellular loop between the third and fourth TM domains also plays an important role, interacting with regulatory kinases and other proteins that keep the receptor anchored in the correct position [Jacob et al., 2008] .
The GABRB2 variant occurring in our patient has key structural and functional implications. The M79 position of GABRB2 is conserved with the other two b subunits of the GABA A receptor (GABRB1 and GABRB3) (see Fig. 2b ), and GABRB2 has overall strong sequence identity to both GABRB1 (77.8% identity) and GABRB3 (79.9% identity). Therefore, alterations in equivalent regions to the M79 position in the other GABA A b subunits presumably have similar functional impacts. The position of the variant M79T lies in the large N-terminal extracellular domain, which has been implicated in GABA binding [Jacob et al., 2008] . Moreover, based on structural comparisons between human GABRB2 and the C. elegans glutamate-gated chloride channel GluCla, this residue may be in close proximity to structural regions that play a role in ligand binding as well as allosteric changes between the neurotransmitter site and transmembrane pore. Given the essential role of this motif, this variant may reduce the function of the GABA A receptor, impairing fast synaptic inhibition and increasing susceptibility to seizure activity. Mutations in GABA A receptor subunits can affect one of several steps involved in the formation of a fully functional receptor, although the precise molecular defect caused by the M79T variant is open to speculation. The steps that are necessary for this process include subunit synthesis, receptor oligomerization/assembly, and receptor trafficking. Impaired oligomerization is the postulated mechanism underlying many different GABA A receptor missense mutations associated with genetic generalized epilepsies [Macdonald and Kang, 2012] , so this defect could also be present in the M79T variant. Another possible molecular explanation for the M79T variant is that subunit oligomerization proceeds normally, in spite of the defective subunit, and the receptor traffics to the membrane, but gating is somehow altered because of b2 subunit dysfunction. More data is needed to support one hypothesis over another. Moreover, it is also unclear why epileptogenesis occurs gradually, even though b2 expression is ubiquitous throughout development [Fritschy et al., 1994] .
From a clinical standpoint, variants in the genes encoding other GABA A receptor subunits besides the b2 subunit, particularly the a1, a6, b3, g2, and d subunits, are the cause of a number of epilepsy syndromes (see Table II ). These syndromes include childhood absence epilepsy (CAE), Dravet syndrome (DS), febrile seizures (FS), generalized epilepsy with febrile seizures plus (GEFS þ ), infantile spams (IS), juvenile myoclonic epilepsy (JME), and Lennox-Gastaut syndrome (LGS). In some studies, the patients were labeled as having idiopathic generalized epilepsy (IGE) which can subsume some of the aforementioned syndromes. Among the different kinds of GABA A receptor coding mutations associated with epilepsy, heterozygous missense mutations (in GABRA1, GABRA6, GABRB3, GABRG2, GABRD) are prevalent, though nonsense mutations (in GABRG2) and frameshift mutations (in GABRA1) can also occur. In some instances of epilepsy, mutations in untranslated sequences can affect the splice sites of GABRA1 and GABRG2 and the 5' upstream promoter regions of GABRB3. IS and LGS, two childhood epileptic encephalopathy syndromes featuring severe epilepsy and neurobehavioral problems, have been associated with defects in GABRA1 (IS) and GABRB3 (IS and LGS).
Our patient presented with a pattern of seizures that may fall under the spectrum of GEFS 
persist past the age of 6 years and/or are accompanied by afebrile generalized tonic-clonic seizures) [Singh et al., 1999] . Her clinical course falls into the latter: she developed febrile seizures in infancy, which resolved, but she went on to develop generalized epilepsy. There is significant phenotypic variability in GEFS þ , and up to 33% of affected individuals may present with other seizure types, including absence, partial, atonic, and myoclonic seizures [Scheffer and Berkovic, 1997; Singh et al., 1999] . GEFS þ is an autosomal dominant channelopathy that can affect several members of a family or arise spontaneously from de novo mutations. Thus far, a handful of mutations have been identified as the cause of GEFS þ , and these impact both sodium channels (in the case of SCN1A, SCN1B, and SCN2A mutations) and the GABA A receptor (in the case of GABRG2 mutations) . The mechanisms of pathogenicity involve either enhanced excitatory neurotransmission (in the case of sodium channel mutations) or decreased synaptic inhibition (in the case of GABA A receptor mutations), both of which contribute to neuronal hyperexcitability. The variant occurring in the proband points to the possibility of dysfunction in the b2 subunit of the GABA A receptor (previously unreported in relation with generalized epilepsy and/or febrile seizures) as another potential cause of GEFS þ . Cognitive impairment is evident in our patient, but the mechanism by which this has occurred is unclear. Animal models suggest that the a5 subunit of the GABA A receptor has an important part in learning and memory [Collinson et al., 2002; Martin et al., 2010] . Surprisingly, adult mice lacking the b2 subunit of the GABA A receptor have no significant phenotypic abnormalities or spontaneous seizures [Sur et al., 2001] . There are limited data in human studies about the specific effects of a defective b2 subunit on cognitive processes like memory and learning, and more research is warranted.
One potential caveat to our report is the emerging idea that variants in other ion channel genes can influence neurological phenotypes, including epilepsy. In an exome sequencing study of 237 channel genes in both unaffected controls and patients with sporadic idiopathic epilepsy, missense mutations were prevalent in both patients and the controls. In fact, 66.9% of the controls had a missense mutation in at least one ion channel gene known to cause familial human epilepsy (among the GABA A receptor genes, these include GABRA1, GABRB3, and GABRG2), versus 96.1% of the patients. In addition, 5% of controls had at least two non-synonymous single nucleotide polymorphisms in GABRB1, GABRB2, or GABRB3 versus 14.5% of the affected patients [Klassen et al., 2011] . Thus, an epileptic phenotype attributed to an ion channel gene mutation may actually be the result of the complex interaction of multiple ion channel gene variants (and gene variants in other biological systems) with each other. A similar argument can be . *The variants in each subunit are designated with respect to the precursor peptide sequence, which includes a signal sequence that is normally cleaved in the mature protein .
made explaining the normal phenotype of unaffected individuals who harbor deleterious ion channel mutations; the end result of this complex gene network interaction is rescuing of the deleterious effects of individual mutations. In our case, besides the single GABRB2 variant, there were no other deleterious mutations detected (including in other ion channel genes), and in light of all the aforementioned evidence, specifically that the variant had occurred de novo in a highly conserved position, we believe that the patient's neurological phenotype is due to the effects of the M79T variant.
In summary, our case represents the first report of a missense mutation in the b2 subunit of the GABA A receptor as a cause of genetic epilepsy and intellectual disability. Our findings underscore the need for further investigation into the mechanisms by which mutations in this GABA A receptor subunit contribute to neurological and developmental dysfunction.
